Cargando…

Improvement of otologic symptoms associated with mRNA COVID-19 vaccines with corticosteroid treatment

Detalles Bibliográficos
Autor principal:	Ma, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186974/ http://dx.doi.org/10.1016/j.mcpsp.2023.100390

Ejemplares similares

Brief review of the mRNA vaccines COVID-19
por: Vitiello, Antonio, et al.
Publicado: (2021)

Myocarditis following COVID-19 mRNA vaccination
por: Abu Mouch, Saif, et al.
Publicado: (2021)

COVID-19 and ear endoscopy in otologic practices
por: Ayache, Stephane, et al.
Publicado: (2020)

Response to mRNA COVID-19 vaccination in three XLA patients
por: Squire, J.D., et al.
Publicado: (2022)

Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients
por: Advani, Pooja, et al.
Publicado: (2021)

Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272
por: Bozzi, Giorgio, et al.
Publicado: (2021)

Healthcare workers benefit from second dose of COVID-19 mRNA vaccine: Effects of partial and full vaccination on sick leave duration and symptoms
por: Strum, Earl, et al.
Publicado: (2022)

Humoral immune response to COVID-19 mRNA vaccination in relation to selenium status
por: Demircan, Kamil, et al.
Publicado: (2022)

New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure
por: Toljan, Karlo, et al.
Publicado: (2022)

Research and Nonresearch Industry Payments for COVID-19 mRNA Vaccines in the United States
por: Murayama, Anju, et al.
Publicado: (2023)

Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site
por: Myles, Ian A, et al.
Publicado: (2021)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights
por: Selvaraj, Gurudeeban, et al.
Publicado: (2021)

Acute myocarditis following a third dose of COVID-19 mRNA vaccination in adults
por: Simone, Anthony, et al.
Publicado: (2022)

BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity
por: Vizcarra, Pilar, et al.
Publicado: (2021)

Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study
por: García-Grimshaw, Miguel, et al.
Publicado: (2021)

Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination
por: Robinson, Lacey B., et al.
Publicado: (2021)

Improving the standardization of mRNA measurement by RT-qPCR
por: Sanders, Rebecca, et al.
Publicado: (2018)

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
por: Zaqout, Ahmed, et al.
Publicado: (2021)

Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration
por: Desai, Aditya P., et al.
Publicado: (2021)

Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection
por: Bongiovanni, Marco, et al.
Publicado: (2021)

Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19
por: Brosh-Nissimov, Tal, et al.
Publicado: (2021)

COVID-19 mRNA vaccine-associated encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: A case report
por: Asaduzzaman, Md, et al.
Publicado: (2022)

Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)
por: Welsh, Kerry J., et al.
Publicado: (2021)

SARS‐CoV‐2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID‐19 vaccination
por: Castruita, Jose Alfredo Samaniego, et al.
Publicado: (2023)

Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
por: Luczkowiak, Joanna, et al.
Publicado: (2022)

Corticosteroids and mRNA Vaccines: A Word of Caution
por: Zhong, Zifu, et al.
Publicado: (2021)

Acute Generalized Exanthematous Pustulosis in Close Temporal Association with mRNA-1273 Vaccine
por: MITRI, Fouad, et al.
Publicado: (2021)

Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients
por: Abbate, Antonio, et al.
Publicado: (2021)

Smoking habits predict adverse effects after mRNA COVID-19 vaccine: Empirical evidence from a pilot study
por: Ponticelli, D., et al.
Publicado: (2023)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Characterization of otologic symptoms appearing after COVID-19 vaccination
por: Leong, Stephen, et al.
Publicado: (2023)

Alert Cards to improve awareness of an otological emergency
por: Brown, Joshua James, et al.
Publicado: (2021)

Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines
por: Botton, Jérémie, et al.
Publicado: (2022)

COVID-19 mRNA vaccine BNT162b2 induces autoantibodies against type I interferons in a healthy woman
por: Ning, Wangbin, et al.
Publicado: (2022)

Effectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric Population
por: Genç Bahçe, Yasemin, et al.
Publicado: (2023)

Temporomandibular treatments are significantly efficient in improving otologic symptoms
por: Naderi, Yeganeh, et al.
Publicado: (2023)

Myocarditis following mRNA vaccination against SARS-CoV-2, a case series
por: King, William W., et al.
Publicado: (2021)

Serological response to a single dose of a SARS-CoV-2 mRNA vaccine
por: Ramos, Angélica, et al.
Publicado: (2021)

Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study
por: Kontopoulou, Konstantina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o42ngpj5v85gv56vea8gnrsi0q